Re: MammoSite Division
I can't speak to the Hologic culture or pay scale, but I can comment on the breast brachytherapy products and market. Both the MammoSite and MammoSite ML are inferior to the competitions' products - Contura (SenoRx/CR Bard) and SAVI (Cianna Medical). That said, MammoSite is still the market leader although their market share is rapidly eroding. After some initial strong growth, Contura sales have flattened or possibly fallen off to some degree. SAVI seems to be gaining traction and their market share is rapidly increasing.
The breast brachytherapy market after 18 months of stalled growth is about to take off again. The data supporting APBI continues to mature. In fact, Hologic issued a press release earlier this month touting the five year results of the ASBS MammoSite Registry. Initial findings for the NSABP B-39 trial should begin reporting in early 2012. Additionally, as women learn more about a 5 day option, demand will increase. Reimbursement has been stable for the past two years and is slated for a minor increase in 2011.
Combining the emerging data, patient awareness and reimbursement, I would say the outlook is very positive for APBI.
Good luck with your job search.